NDANASALAEROSOL, METEREDPriority Review
Approved
Sep 1981
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
Priority Review
VANCENASE (beclomethasone dipropionate) by Merck & Co. is anti-inflammatory activity. Approved for asthma, allergic rhinitis. First approved in 1981.
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Vancenase (beclomethasone dipropionate) is a metered-dose nasal aerosol corticosteroid approved in 1981 for asthma and allergic rhinitis. It works by inhibiting inflammatory cells and mediators through glucocorticoid receptor binding, with the active metabolite 17-BMP showing high receptor affinity. The drug demonstrates a favorable ratio of topical anti-inflammatory to systemic effects at recommended doses.
LOE Approaching
As LOE approaches, the Vancenase brand team will prioritize generic containment and lifecycle extension strategies, likely resulting in smaller team sizes and budget reallocations.
Mechanism of Action
anti-inflammatory activity. The precise mechanism of corticosteroid action on asthma is not known. Corticosteroids have been shown to have multiple anti-inflammatory effects, inhibiting both inflammatory cells (e.g., mast cells, eosinophils, basophils, lymphocytes, macrophages, and neutrophils) and…
Indications (2)
Worked on VANCENASE at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.